Nialamide and Sulindac share 8 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.320 means 32% of the combined target set is bound by both compounds. The IDF-weighted score of 0.245 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Nialamide and Sulindac have in common?
Nialamide and Sulindac share 8 molecular targets with a Jaccard similarity of 32%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Nialamide and Sulindac be combined?
Nialamide and Sulindac share 8 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Nialamide or Sulindac?
Both Nialamide and Sulindac have substantial PubMed research. View their individual profiles for full evidence scores.